AbCellera Biologics Inc. cash flow to debt ratio of -91.67% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

AbCellera Biologics Inc.'s free cash flow has increased -6.89% from $-186.95M last year to $-174.07M, signaling increasing performance

AbCellera Biologics Inc.'s debt to equity ratio is 0.15, which means that the company's assets are healthy financed, signaling financial stability.

AbCellera Biologics Inc.'s debt has increased relative to shareholder equity from 0.06 last year to 0.15 today, signaling weakened financials

AbCellera Biologics Inc. has a net cash position, so leverage is healthy.

AbCellera Biologics Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

AbCellera Biologics Inc.'s profit margin has increased (-55.95%) in the last year from -564.83% to -248.83%, signaling increasing performance

AbCellera Biologics Inc.'s short-term assets of $728.23M exceed its short-term liabilities of $64.31M

AbCellera Biologics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

AbCellera Biologics Inc.'s return on equity of -17.49%, is lower than 15.00%, indicating bad performance

AbCellera Biologics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

AbCellera Biologics Inc. had positive net income in only 2 out of 5 years, indicating unstable earnings

AbCellera Biologics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

AbCellera Biologics Inc. has negative free cash flow, indicating cash burn

AbCellera Biologics Inc.'s yearly earnings has increased -10.10% since last year from $-162.86M to $-146.41M, signaling increasing performance

AbCellera Biologics Inc.'s yearly revenue has increased 160.56% since last year from $28.83M to $75.13M, signaling increasing performance

ROIC -14.95% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

AbCellera Biologics Inc.'s 3-year revenue CAGR of -46.31% is negative, indicating declining revenue over the past 3 years

AbCellera Biologics Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

AbCellera Biologics Inc. had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

AbCellera Biologics Inc. has insufficient data to evaluate this check.

AbCellera Biologics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

AbCellera Biologics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

AbCellera Biologics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

AbCellera Biologics Inc. has insufficient data to evaluate this check.

AbCellera Biologics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

AbCellera Biologics Inc. has a price-to-book ratio of 3.19x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

AbCellera Biologics Inc. has a price-to-sales ratio of 43.12x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue